Stay updated with breaking news from Braf V600e. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Marcia Brose, MD, examines data from the COSMIC-311 study, emphasizing the importance of promptly initiating second-line therapy for patients who have progressed on first-line treatments.
The FDA has approved encorafenib (Braftovi) plus binimetinib (Mektovi) for adult patients with metastatic non–small cell lung cancer harboring a BRAF V600E mutation, as detected by an FDA-approved test.
The FDA has granted fast track designation to ABM-1310 for the treatment of patients with glioblastoma harboring BRAF V600E mutations.
A rolling new drug application seeking the approval of tovorafenib monotherapy for the treatment of patients with relapsed or progressive pediatric low-grade glioma has been submitted to the FDA.
Triplet therapy consisting of encorafenib, cetuximab, and binimetinib demonstrated activity and manageable safety as first-line treatment for patients with BRAF V600E–mutated metastatic colorectal cancer.